Anavex Life Sciences Beheer
Beheer criteriumcontroles 4/4
De CEO Anavex Life Sciences is Chris Missling, benoemd in Jul2013, heeft een ambtstermijn van 11.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.89M, bestaande uit 18% salaris en 82% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.47% van de aandelen van het bedrijf, ter waarde $ 9.74M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 10.5 jaar.
Belangrijke informatie
Chris Missling
Algemeen directeur
US$3.9m
Totale compensatie
| Percentage CEO-salaris | 18.0% |
| Dienstverband CEO | 11.3yrs |
| Eigendom CEO | 1.5% |
| Management gemiddelde ambtstermijn | 2.8yrs |
| Gemiddelde ambtstermijn bestuur | 10.5yrs |
Recente managementupdates
Recent updates
Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Nov 05Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Oct 08Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Jul 29Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Jul 17
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Apr 01Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Sep 19We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 10Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Jan 16We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Oct 01Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia
Sep 19Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease
Sep 07Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01
Aug 09We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Jun 17Anavex: Increasing Shareholder Value Against All Odds
May 31Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
Mar 23We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Mar 03Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease
Feb 09Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
Feb 02Anavex: 2022 Has Major, Pivotal Catalysts
Jan 17Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Nov 16Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Nov 05Anavex Life Sciences: Still Room To Run
Aug 29Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Jul 30Anavex: A Catalyst-Rich Year
Jul 05Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers
Jun 21Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease
Jun 14Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment
Jun 08Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease
Apr 28Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Apr 16Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$42m |
| Mar 31 2024 | n/a | n/a | -US$41m |
| Dec 31 2023 | n/a | n/a | -US$43m |
| Sep 30 2023 | US$4m | US$700k | -US$48m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$53m |
| Dec 31 2022 | n/a | n/a | -US$50m |
| Sep 30 2022 | US$7m | US$586k | -US$48m |
| Jun 30 2022 | n/a | n/a | -US$45m |
| Mar 31 2022 | n/a | n/a | -US$43m |
| Dec 31 2021 | n/a | n/a | -US$41m |
| Sep 30 2021 | US$9m | US$550k | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | n/a | n/a | -US$28m |
| Sep 30 2020 | US$2m | US$550k | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | n/a | n/a | -US$26m |
| Sep 30 2019 | US$3m | US$513k | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$26m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | n/a | n/a | -US$20m |
| Sep 30 2018 | US$3m | US$500k | -US$17m |
Compensatie versus markt: De totale vergoeding ($USD 3.89M ) Chris } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.18M ).
Compensatie versus inkomsten: De vergoeding van Chris is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Chris Missling (58 yo)
11.3yrs
Tenure
US$3,894,453
Compensatie
Dr. Christopher U. Missling, also known as the Chris, MS, Ph D., MBA, has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and also serves as its Director an...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 11.3yrs | US$3.89m | 1.47% $ 9.7m | |
| Principal Financial Officer & Treasurer | 9.1yrs | US$501.06k | 0.027% $ 178.9k | |
| Chief Scientific Officer | 2.8yrs | geen gegevens | geen gegevens | |
| VP of Corporate | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Nonclinical Development | 3.5yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer | 2.8yrs | geen gegevens | geen gegevens | |
| Head of Biostatistics | 1.7yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Regulatory Affairs | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Clinical Development | less than a year | geen gegevens | geen gegevens | |
| Senior VP & Head of Research and Development | less than a year | geen gegevens | geen gegevens |
2.8yrs
Gemiddelde duur
Ervaren management: Het managementteam van AVXL wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 11.3yrs | US$3.89m | 1.47% $ 9.7m | |
| Independent Chairman | 3.5yrs | US$349.54k | geen gegevens | |
| Member of the Scientific Advisory Board | 9.7yrs | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | 13.8yrs | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | 10.9yrs | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | 11yrs | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 11.8yrs | US$341.54k | 1.54% $ 10.2m | |
| Member of the Scientific Advisory Board | 10.5yrs | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | 9.7yrs | geen gegevens | geen gegevens | |
| Independent Director | 9.4yrs | US$341.54k | 0.0059% $ 39.0k | |
| Lead Independent Director | 6.7yrs | US$357.54k | geen gegevens |
10.5yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van AVXL zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.5 jaar).